NCT06029218 (P1V2) is a NA clinical trial of Proteus ONE one daily beam in Chordoma, sponsored by Centre Antoine Lacassagne.

Who is sponsoring NCT06029218?

NCT06029218 is sponsored by Centre Antoine Lacassagne.

What drugs are being tested in NCT06029218?

Interventions in NCT06029218: Proteus ONE one daily beam, Proteus ONE two daily beam.

What condition does NCT06029218 study?

NCT06029218 studies Chordoma, Chondrosarcoma, Ewing Sarcoma, Osteosarcoma.

Is NCT06029218 still recruiting?

NCT06029218 is currently recruiting now. Last updated 25 September 2024.

Last reviewed 2024-09-25 · How we verify

NCT06029218: P1V2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy

Recruiting now NA Last updated 25 September 2024

What this trial tests

NA trial testing Proteus ONE one daily beam in Chordoma in 106 participants. Currently enrolling.

Timeline

13 September 2023

Primary endpoint
1 September 2026

1 October 2031

Quick facts

Lead sponsor	Centre Antoine Lacassagne
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	106
Start date	13 September 2023
Primary completion	1 September 2026
Estimated completion	1 October 2031
Sites	1 location across France

Drugs / interventions tested

Proteus ONE one daily beam
Proteus ONE two daily beam

Conditions studied

Chordoma — all drugs for Chordoma →
Chondrosarcoma — all drugs for Chondrosarcoma →
Ewing Sarcoma — all drugs for Ewing Sarcoma →
Osteosarcoma — all drugs for Osteosarcoma →

Sponsor

Centre Antoine Lacassagne — full company profile →

Who can join

18 and older, any sex, with Chordoma or Chondrosarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Thanks to the intrinsic qualities of the proton beam, proton therapy will reduce adverse effects of irradiation. The Proteus®One is the latest generation of proton therapy equipment, enabling the Centre Antoine Lacassagne to expand its range of treatments by carrying out new proton therapy treatments. It has an innovative compact isocentric rotating head (Gantry) that allows the radiation beam to be directed at different angles around the patient. In some cases, two beams are used to treat tumours, and by convention, both beams are delivered during the same session. However, it is necessary to position the patient before each beam, which is time-consuming because 2 beams have to be positioned very precisely each day. The aim of this study is therefore to assess the toxicity of proton therapy delivered by a single daily beam compared with proton therapy delivered by two daily beams, which is the conventional technique.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Chordoma: Genetics and Contemporary Management.
Desai R, Pelargos PE, Dunn IF. · · 2024 · cited 15× · PMID 38892063 · DOI 10.3390/ijms25115877

Verify or expand the search:

Other recruiting trials for Chordoma

Currently open trials in the same condition.

NCT05407441 — Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors · Phase 1, PHASE2 · active not recruiting
NCT05861245 — Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base · NA · recruiting
NCT05041127 — Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma · Phase 2 · active not recruiting
NCT05033288 — Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone · recruiting
NCT04087902 — Long-Term Longitudinal QoL in Patients Undergoing EEA · recruiting

Other Centre Antoine Lacassagne trials

Trials by the same sponsor.

NCT07429487 — Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fati · NA · not yet recruiting
NCT06782451 — Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity · NA · recruiting
NCT06606366 — Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplina · NA · recruiting
NCT06400849 — Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy · NA · recruiting
NCT06058312 — Individual Food Preferences for the Mediterranean Diet in Cancer Patients · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06029218 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Antoine Lacassagne
Last refreshed: 25 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06029218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing